Search Results

If approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma

Corporate

July 2, 2013

Mentor Announces Collaboration Agreement With Valeant Pharmaceuticals

New physician loyalty program offers broad portfolio of aesthetic products

Innovative Medicine

June 28, 2013

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

Innovative Medicine

June 28, 2013

CHMP Gives A Positive Opinion For The Use Of VELCADE® As Retreatment And For Frontline Induction Therapy Before Stem Cell Transplantation

Label updates could lead to significantly improved outcomes for patients with multiple myeloma

Innovative Medicine

June 24, 2013

Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes

Phase 3 Results for INVOKANA™ Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine